WeightLoss

Lilly Seeks Court Action Against Compounded Copies of Its Popular Weight-Loss Medications

by

Indianapolis-based pharmaceutical giant Eli Lilly and Co. has requested to join a lawsuit targeting manufacturers of compounded versions of its popular weight-loss drugs. The company alleges that these compounded versions might pose safety risks and infringe on its intellectual property rights. This legal move comes as the U.S. weight-loss drug market experiences significant growth, driven by increasing awareness and consumer demand for effective obesity treatments. The lawsuit, originally filed by the U.S. Department of Justice, seeks to halt the production and distribution of unauthorized compounded versions of drugs similar to Lilly’s FDA-approved offerings, including Mounjaro … Read more

Exploring Legal Strategies for GLP-1 Weight-Loss Drug Manufacturers in the U.S. Mass Tort Arena

by

New York — As the rates of obesity continue to climb at an alarming rate worldwide, pharmaceutical companies have intensified their efforts in advancing medications targeted at weight management. Among these, glucagon-like peptide-1 receptor (GLP-1) weight-loss drugs have been gaining attention not just for their efficacy but also for the litigation challenges they may face. Historically, the American mass tort litigation landscape offers extensive insights that are invaluable for these manufacturers in navigating potential legal battles. In the U.S., mass tort claims have frequently emerged in the pharmaceutical sector, with companies often finding themselves entangled … Read more

Weight-Loss Drug Makers Navigate U.S. Litigation Landscape: Lessons from the Past and Strategies for Future Defense

by

Washington, D.C. – Amid booming sales, manufacturers of GLP-1 weight-loss drugs face a new challenge: the potential for mass tort litigation similar to what has historically rocked other sectors of the American pharmaceutical industry. Industry experts suggest that drawing lessons from past litigations could be key to these manufacturers not just surviving but thriving in an increasingly litigious environment. GLP-1, or glucagon-like peptide-1 receptor agonists, have gained attention not only for their effectiveness in obesity management but also for potential side effects which could become the focal point of legal battles. Given the aggressive nature … Read more

Emerging Legal Battles: Surge in Litigation Anticipated Over Weight-Loss Medications

by

In recent developments across the pharmaceutical industry, weight-loss medications are under increasing scrutiny as they potentially become the focal point of significant mass tort litigation. These drugs, designed to aid individuals in losing weight, have become popular solutions for battling obesity, a mounting health crisis in the United States. Among the pharmaceutical offerings currently receiving attention, weight-loss drugs such as Wegovy and Ozempic have surged in popularity. Marketed extensively, these medications promise to help users reduce their weight significantly when combined with exercise and a healthy diet. However, their rise in popularity has led to … Read more